Gastroparesis drugs market to increase by $1.42b by 2028

It is driven by rising diabetes rates.

The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with a 3.69% annual growth rate, according to Technavio.

The expansion is fuelled by a global increase in diabetes, a major contributor to gastroparesis cases.

The report said that vendors in the gastrointestinal drugs market are increasingly targeting emerging economies to address the growing number of undiagnosed and untreated patients with gastrointestinal disorders.  The incidence of chronic gastrointestinal conditions, including gastroparesis, is on the rise in Asia, particularly in China and India.

However, strict regulatory guidelines may slow down progress, adding challenges for manufacturers.

Regulatory bodies, including the US FDA and EMA, require extensive testing for drug safety and efficacy, which adds costs and delays. Clinical trials are rigorous, with multiple phases that demand large financial investments and adherence to stringent good manufacturing practices (GMP).

Gastroparesis, marked by symptoms like nausea, vomiting, and nutrient absorption issues, is also a growing concern.

FDA-approved drugs such as tradipant, metopimazine, and metoclopramide are gaining traction, whilst new treatments are in trials to manage symptoms tied to diabetes and post-surgical complications.